Search Results

1,400 Results for "samsung neurologica".

Sort By

Policy

FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar to Stelara

Samsung Bioepis Co., Ltd. announced that the U.S. Food and Drug Administration has approved the Biologics License Application for PYZCHIVA® subcutaneous injection and intravenous infusion as a biosimilar to Stelara.

July 1, 2024
·
10 min read
Deals

Samsung Bio Nabs $1B Manufacturing Contract With Undisclosed US Pharma

Samsung Biologics announced Tuesday it has signed its largest contract ever—a $1.06 billion manufacturing deal with an unnamed pharmaceutical company headquartered in the U.S.

July 2, 2024
·
2 min read
·
Tristan Manalac
FDA

Samsung Bioepis Gets FDA Approval for Biosimilar of J&J’s Stelara

Pyzchiva, developed by Samsung Bioepis, will be commercialized in the U.S. by Sandoz with the license period beginning on Feb. 22, 2025, according to a settlement and licensing agreement with Johnson & Johnson’s Janssen Biotech.

July 1, 2024
·
1 min read
·
Tyler Patchen
Genetown

NeuroLogica Corp Receives Innovative Technology Designation from Vizient for OmniTom Elite PCD

NeuroLogica Corp. announces its OmniTom Elite PCD has received an Innovative Technology designation from Vizient, Inc., the largest provider-driven healthcare performance improvement company in the country.

January 11, 2024
·
3 min read
Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation

Samsung Bioepis Co., Ltd. issued its 2024 sustainability report, underscoring its progress toward building more sustainable and socially responsible practices in access to medicines, R&D innovation, and product quality and patient safety.

June 25, 2024
·
5 min read
Business

Samsung Biologics Reports First Quarter 2024 Financial Results

Samsung Biologics, a global contract development and manufacturing organization, announced financial results for the first quarter of fiscal year 2024.

April 24, 2024
·
4 min read
Genetown

Samsung Invests in BrickBio to Develop Advanced Molecules and Therapies Using Protein Engineering Technology for Antibody-Drug Conjugates (ADC)

Samsung Life Science Fund, created jointly between Samsung Biologics, Samsung Bioepis, and Samsung C&T, and managed by Samsung Ventures, and BrickBio, Inc. announced Samsung’s investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code.

March 18, 2024
·
3 min read
Genetown

Samsung Accepts Healthcare Innovator Award for Contribution to Care in Underserved Communities

Boston Imaging, the United States headquarters of Samsung’s digital radiography and ultrasound business, was awarded HHM Health’s Healthcare Innovator Award for its SonoSync technology and contributions to closing the gap in quality, accessible healthcare for underserved communities.

March 20, 2024
·
4 min read
Drug Development

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™

September 20, 2024
·
8 min read
Genetown

Samsung Ushers in a New Era of Diagnostic Solutions at RSNA 2023

Samsung will feature the latest innovation in cutting-edge mobile computed tomography, including the state-of-the-art OmniTom Elite with Photon Counting Detector (PCD) technology.

November 21, 2023
·
5 min read